Fluorouracil and Palmar-Plantar Erythrodysesthesia

Curran, Charles F.

doi:10.7326/0003-4819-111-10-858_1

Cited by 22 publications

(6 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, several studies of 5-FU have found that bolus dosing corresponds with a lower risk of HFS than does continuous infusion [5,19,20,33,82]. However, bolus administration has been observed to correspond with more rapid and more severe HFS [6].…”

Section: Risk Factorsmentioning

confidence: 99%

“…Most studies of patients with HFS reported that resumption of therapy at the prior dose caused symptom relapse [5,70,79,83], although some patients do remain free of HFS after restarting the drug without dose reduction [82], including patients with HFS from sorafenib [13]. In the vast majority of case series, no long-term sequelae were noted during the follow-up after resolution of the HFS symptoms in their patients [5,25,77,87].…”

Section: Managementmentioning

confidence: 99%

See 1 more Smart Citation

Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib

Lipworth¹,

2009

View full text Add to dashboard Cite

Hand-foot syndrome (HFS), also called hand-foot skin reaction, palmar-plantar erythrodysesthesia, acral erythema, and Burgdorf reaction, is a dose-limiting cutaneous toxicity of many chemotherapeutic agents. Recently, the multiple tyrosine kinase inhibitor class of novel targeted therapies, including sorafenib and sunitinib, has emerged as an important cause of HFS, with 10–28% of patients treated with sunitinib and 10–62% of patients treated with sorafenib reporting HFS. This review examines the epidemiology, clinical features, histopathology, pathogenesis models, prognostic implications, and management of HFS, with particular attention to HFS induced by sorafenib and sunitinib. The high prevalence of HFS reported by patients treated with these medications underscores the need for greater understanding of the pathogenesis and management of this syndrome.

show abstract

Section: Risk Factorsmentioning

confidence: 99%

Section: Managementmentioning

confidence: 99%

Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib

Lipworth¹,

2009

View full text Add to dashboard Cite

show abstract

“…This indicates that a complex mechanism is responsible for the induction of this condition. We report here three cases of chemotherapy- (3,5,20,25,30,31) Peculiar acral erythema (2) Distinctive acral erythema (10) Chemotherapy-induced acral erythema (18,23,24,29) Painful red hands (21) Erythema and desquamation (4) Palmar-plantar erythema (11,12) Palmar-plantar erythrodysesthesia (7,13,14,15,22,27,28) Toxic erythema of palms and soles (19) Erythematous eruption ofthe palms and soles (1) Dermatitis of the hands and feet (9) Hand-foot syndrome (8,26) Burgdorf's reaction (24) induced acral erythema.…”

Section: Introductionmentioning

confidence: 99%

Three Cases of Chemotherapy‐induced Acral Erythema

Komamura

Higashiyama

Hashimoto

et al. 1995

The Journal of Dermatology

View full text Add to dashboard Cite

Three cases of chemotherapy-induced acral erythema are reported. All the patients had received cyclophosphamide, vincristine, adriamycin, prednisolone, and granulocyte-colony stimulating factor (G-CSF) for the treatment of leukemia or malignant lymphoma. From 35 to 45 days after the start of chemotherapy, painful erythematous lesions developed on their palms, soles, fingers, and toes, resulting in blister formation and desquamation. The recent higher incidence of chemotherapy-induced acral erythema may be correlated with the popularity of G-CSF, which allows the use of higher doses of chemotherapeutic drugs.

show abstract

“…He also developed sensory peripheral neuropathy around the same time, but extensive work-up disclosed no clear etiology. A serious adverse effect, erythrodysesthesia, has also been reported [3]. Dihydropyrimidine dehydrogenase activity was evaluated in the peripheral mononuclear cells both by radioassay and by [2-13 C] uracil breath test.…”

mentioning

confidence: 99%

Peripheral neuropathy exacerbation associated with topical 5-fluorouracil

Saif¹,

Hashmi²,

Mattison³

et al. 2006

Anti-Cancer Drugs

View full text Add to dashboard Cite

Peripheral neuropathy secondary to 5-flourouracil and capecitabine (Xeloda) has been reported. We report the first case of exacerbation of peripheral neuropathy related to topical 5-flourouracil (Efudex). A 70-year-old Caucasian male with a history of actinic keratosis for 15 years was treated intermittently with topical application of 5-flourouracil. He also developed sensory peripheral neuropathy around the same time, but extensive work-up disclosed no clear etiology. In early 2005, he developed an exacerbation of his peripheral neuropathy following a 21-day course of topical 5-flourouracil for actinic keratosis, especially pain and parasthesias. Dihydropyrimidine dehydrogenase activity was evaluated in the peripheral mononuclear cells both by radioassay and by [2-C] uracil breath test. Dihydropyrimidine dehydrogenase activity was within the normal range by both methods. Stopping topical 5-flourouracil resolved the symptoms to baseline. Instead of topical 5-flourouracil, topical imiquimod was used which did not exacerbate his neuropathy. He was not re-challenged with topical 5-flourouracil. Topical 5-flourouracil has been known to cause mainly dermatological adverse effects, but systemic effects because of absorption are possible, especially in dihydropyrimidine dehydrogenase-deficient patients. As our patient had no other cause responsible for his neuropathy, the onset of symptoms coincided historically with topical application of 5-flourouracil and the 5-flourouracil usage preceded an exacerbation of sensory symptoms, we conclude that this drug was responsible for his polyneuropathy.

show abstract

Fluorouracil and Palmar-Plantar Erythrodysesthesia

Cited by 22 publications

References 3 publications

Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib

Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib

Three Cases of Chemotherapy‐induced Acral Erythema

Peripheral neuropathy exacerbation associated with topical 5-fluorouracil

Contact Info

Product

Resources

About